Arizona Cancer Research Alliance & 21st Century Oncology To Enroll Patients In CEL-SCI (CVM)’s Global Phase 3 Head and Neck Cancer Trial
4/2/2014 11:02:58 AM
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) today announced it has expanded its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in the U.S. with the addition of a new site in Scottsdale, Arizona. The 21st Century Oncology clinic in Scottsdale, along with the Arizona Cancer Research Alliance, has just joined the study and is actively screening patients for enrollment into the trial. The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by